About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Study of BMS-986158 in Subjects With Select Advanced Cancers

Study of BMS-986158 in Subjects With Select Advanced Cancers

NCT02419417·13 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Bristol-Myers Squibb

Age

12–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Must have select advanced cancers with specific genetic profiles
Must have received appropriate standard of care
At least one measurable lesion at baseline
Expected to have life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) of 0 to 1

You may not be if

Concomitant second malignancies
Uncontrolled or significant cardiovascular disease
Inadequate bone marrow function
Chronic gastrointestinal illness
Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor

The record

StatusCompleted

PhasePhase 1–2

Taking part83

StartedJun 2015

UpdatedJun 16, 2022

Conditions

Advanced Tumors

Where13

City Of Hope National Medical Center
Duarte, California, United States
University Of Colorado
Aurora, Colorado, United States
Dana Farber Cancer Institute.
Boston, Massachusetts, United States